Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges
Lung cancer, the leading cause of death worldwide, is associated with the highest morbidity. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancer cases. Advances in the domain of cancer treatment have improved the prognosis and quality of life of patients with metastatic NSCLC. Neve...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1523 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850042550073688064 |
|---|---|
| author | Yunyao Ye Shanxun Yu Ting Guo Sihui Zhang Xiaozhou Shen Gaohua Han |
| author_facet | Yunyao Ye Shanxun Yu Ting Guo Sihui Zhang Xiaozhou Shen Gaohua Han |
| author_sort | Yunyao Ye |
| collection | DOAJ |
| description | Lung cancer, the leading cause of death worldwide, is associated with the highest morbidity. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancer cases. Advances in the domain of cancer treatment have improved the prognosis and quality of life of patients with metastatic NSCLC. Nevertheless, tumor progression or metastasis owing to treatment failure caused by primary or secondary drug resistance remains the cause of death in the majority of cases. Epithelial–mesenchymal transition (EMT), a vital biological process wherein epithelial cancer cells lose their inherent adhesion and transform into more invasive mesenchymal-like cells, acts as a powerful engine driving tumor metastasis. EMT can also induce immunosuppression in the tumor environment, thereby promoting cancer development and poor prognosis among patients with NSCLC. This review aims to elucidate the effect of EMT on metastasis and the tumor immune microenvironment. Furthermore, it explores the possible roles of EMT inhibition in improving the treatment efficacy of NSCLC. Targeting EMT may be an ideal mechanism to inhibit tumor growth and progression at multiple steps. |
| format | Article |
| id | doaj-art-42ef29a1f8e8489689ceabc1efbab2de |
| institution | DOAJ |
| issn | 2218-273X |
| language | English |
| publishDate | 2024-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj-art-42ef29a1f8e8489689ceabc1efbab2de2025-08-20T02:55:31ZengMDPI AGBiomolecules2218-273X2024-11-011412152310.3390/biom14121523Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and ChallengesYunyao Ye0Shanxun Yu1Ting Guo2Sihui Zhang3Xiaozhou Shen4Gaohua Han5Department of Oncology, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaDepartment of Oncology, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaCentral Lab, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaDepartment of Oncology, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaDepartment of Oncology, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaDepartment of Oncology, Taizhou People’s Hospital Affiliated to Nanjing Medical University, Taizhou 225300, ChinaLung cancer, the leading cause of death worldwide, is associated with the highest morbidity. Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancer cases. Advances in the domain of cancer treatment have improved the prognosis and quality of life of patients with metastatic NSCLC. Nevertheless, tumor progression or metastasis owing to treatment failure caused by primary or secondary drug resistance remains the cause of death in the majority of cases. Epithelial–mesenchymal transition (EMT), a vital biological process wherein epithelial cancer cells lose their inherent adhesion and transform into more invasive mesenchymal-like cells, acts as a powerful engine driving tumor metastasis. EMT can also induce immunosuppression in the tumor environment, thereby promoting cancer development and poor prognosis among patients with NSCLC. This review aims to elucidate the effect of EMT on metastasis and the tumor immune microenvironment. Furthermore, it explores the possible roles of EMT inhibition in improving the treatment efficacy of NSCLC. Targeting EMT may be an ideal mechanism to inhibit tumor growth and progression at multiple steps.https://www.mdpi.com/2218-273X/14/12/1523epithelial–mesenchymal transitionmetastasistumor immune microenvironmentnon-small cell lung cancerimmune checkpoint inhibitor |
| spellingShingle | Yunyao Ye Shanxun Yu Ting Guo Sihui Zhang Xiaozhou Shen Gaohua Han Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges Biomolecules epithelial–mesenchymal transition metastasis tumor immune microenvironment non-small cell lung cancer immune checkpoint inhibitor |
| title | Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges |
| title_full | Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges |
| title_fullStr | Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges |
| title_full_unstemmed | Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges |
| title_short | Epithelial–Mesenchymal Transition in Non-Small Cell Lung Cancer Management: Opportunities and Challenges |
| title_sort | epithelial mesenchymal transition in non small cell lung cancer management opportunities and challenges |
| topic | epithelial–mesenchymal transition metastasis tumor immune microenvironment non-small cell lung cancer immune checkpoint inhibitor |
| url | https://www.mdpi.com/2218-273X/14/12/1523 |
| work_keys_str_mv | AT yunyaoye epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges AT shanxunyu epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges AT tingguo epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges AT sihuizhang epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges AT xiaozhoushen epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges AT gaohuahan epithelialmesenchymaltransitioninnonsmallcelllungcancermanagementopportunitiesandchallenges |